Clinical Trials Logo
NCT number NCT03423342
Study type Interventional
Source University of Washington
Contact Kevin D O'Brien, MD
Phone 206 685-3930
Email cardiac@uw.edu
Status Recruiting
Phase Phase 1/Phase 2
Start date May 19, 2016
Completion date June 30, 2018

Clinical Trial Summary

Mitochondrial dysfunction has been implicated in heart failure (HF), and is associated with an imbalance in intracellular ratio of reduced nicotinamide-adenine dinucleotide (NADH) to oxidized nicotinamide-adenine dinucleotide (NAD), or the NADH/NAD ratio. In mouse models of HF, we have found that normalization of the NADH/NAD, through supplementation with NAD+ precursors, is associated with improvement in cardiac function. This Study will randomize participants with systolic HF (ejection fraction ≤40%) to treatment with the NAD precursor, nicotinamide riboside (NR) or matching placebo, uptitrated to a final oral dose of 1000mg twice daily, to determine the safety and tolerability of NR in participants with systolic HF.


Clinical Trial Description

Aim 1: Determine the safety and tolerability of NR in patients with clinically stable, systolic heart failure (LVEF <40%). To accomplish this Aim:

A) a total of 30 participants with clinically stable, systolic heart failure (LVEF <40%) will undergo 2:1 randomization to NR 250mg PO twice daily or matching placebo B) NR (or matching placebo), will be increased weekly by 250mg/dose (500mg/day) to a final dose of 1000mg PO twice daily. Clinic visits with labs bi-weekly during dose escalation will assess HF symptoms and monitor labs [B-type natriuretic peptide (BNP), complete blood count (CBC), glycosylated hemoglobin, alanine aminotransferase (ALT), creatine kinase (CK), insulin/glucose, uric acid, electrolytes, blood urea nitrogen (BUN) and creatinine (Cr).

C) to ensure intermediate-term safety and tolerability, participants will continue on their maximum tolerated dose (of NR or placebo) through Study Week 12

Aim 2: Determine whether, at the doses employed, NR and NAD are detectable in whole blood.

Aim 3 (Exploratory): Assess the range of potential effect sizes of NR on HF surrogate endpoints using:

A) Six-minute walk tests (6MWTs) at each visit (including Screening) to assess functional capacity B) Echocardiography at Baseline and Week 12 to assess LV systolic function (by real-time, 3D echocardiography) and diastolic function (by integrated Doppler and tissue Doppler imaging)


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Suspended NCT02997670 - Quartet Lead With Defibrillator Multisite Algorithmic Cardiac Resynchronisation Therapy Optimisation N/A
Recruiting NCT03305692 - ECG Belt vs. Echocardiographic Optimization of CRT N/A
Recruiting NCT02920918 - Treatment of Diabetes in Patients With Systolic Heart Failure Phase 4
Active, not recruiting NCT02334891 - Kyoto Congestive Heart Failure Study N/A
Recruiting NCT03351283 - Effect of Sodium Intake on Brain Natriuretic Peptide Levels in Patients With Heart Failure N/A
Recruiting NCT02973594 - Pulse Reduction On Beta-blocker and Ivabradine Therapy Phase 4
Recruiting NCT02960685 - Telesonography for Visually Estimating Ejection Fraction N/A
Recruiting NCT02579200 - Inspiratory Muscle Training for Breathless Patients With Chronic Obstructive Pulmonary Disease and Heart Failure Phase 4
Active, not recruiting NCT01553045 - Reasons for Variations in Health Related Quality of Life and Symptom Burden in Patients With Atrial Fibrillation N/A
Completed NCT02946476 - Prognostic Impact of Noncardiac Comorbidities in Heart Failure Patients N/A
Recruiting NCT03089502 - Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity N/A
Recruiting NCT03220659 - Optimising Pacemaker Therapy Using Multi-point Pacing (the OPT-MPP Study) N/A
Recruiting NCT03183011 - Cardiac Magnetic Resonance Imaging After Cardiac Resynchronization Therapy N/A
Not yet recruiting NCT03374891 - A Multicenter Trial of a Shared DECision Support Intervention for Patients Offered Implantable Cardioverter-DEfibrillators N/A
Completed NCT02401126 - Effects of Dietary Nitrate Supplementation on Cardiorespiratory Control in Chronic Heart Failure Phase 4
Recruiting NCT02099903 - Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease N/A
Not yet recruiting NCT02026505 - Evaluation of Cardiotoxic Effects of Bortezomib N/A
Completed NCT03073356 - Ketones in Heart Failure - Effects on Cardiac Efficiency Phase 2
Completed NCT03079518 - Intravenous Iron in paTients With Heart failURe and Reduced Ejection fracTion (HFREF) pLus Iron dEficiency Phase 2
Recruiting NCT03183323 - Implementation of Telerehabilitation In Support of HOme-based Physical Exercise for Heart Failure N/A